Review



tlr2 4 inhibitor  (Novus Biologicals)


Bioz Verified Symbol Novus Biologicals is a verified supplier
Bioz Manufacturer Symbol Novus Biologicals manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 92
      Buy from Supplier

    Structured Review

    Novus Biologicals tlr2 4 inhibitor
    Tlr2 4 Inhibitor, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 92/100, based on 7 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tlr2+tlr4+inhibitor/pmc12757294-65-8-11?v=Novus+Biologicals
    Average 92 stars, based on 7 article reviews
    tlr2 4 inhibitor - by Bioz Stars, 2026-07
    92/100 stars

    Images



    Similar Products

    tlr2 4 inhibitor  (Novus Biologicals)
    92
    Novus Biologicals tlr2 4 inhibitor
    Tlr2 4 Inhibitor, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tlr2+tlr4+inhibitor/pmc12757294-65-8-11?v=Novus+Biologicals
    Average 92 stars, based on 1 article reviews
    tlr2 4 inhibitor - by Bioz Stars, 2026-07
    92/100 stars
    		  Buy from Supplier
    tlr4 inhibitor  (Selleck Chemicals)
    93
    Selleck Chemicals tlr4 inhibitor
    Fig. 4 XBP-1s expression in α-synuclein-stimulated DCs. (A, B) mDCs generated from healthy subjects (Table 1) were cultured in the presence or absence of high-dose (50 µg/ml) αS monomers or fibrils for 24 h. XBP-1s expression in CD209+ mDCs was analyzed. Gating strategies are shown in Supplementary Fig. 7. A representative histogram is shown in (A) and the XBP-1 s+ ratio in CD209+ mDCs (n = 7) is shown in (B). (C) Cryopreserved PBMCs from PD patients (n = 8) and age-matched controls (n = 5) were subjected to flow cytometric analysis (Supplementary Table 4). Gating strategies are shown in Supplementary Fig. 12. The XBP-1 s+ ratio in CD1c+ type 2 conventional DCs (cDC2s) is shown. (D–G) mDCs generated from healthy subjects (Table 1, n = 6) were treated with a <t>TLR4</t> inhibitor, TAK-242 (60 µM) (D, E), or an IRE1-XBP-1s inhibitor, STF-083010 (120 µM) (F, G), for 2 h prior to 24 h stimulation with high-dose (50 µg/ml) αS fibrils. Vehicle containing the same concentration of DMSO was used as a control. (D–F) XBP-1s expression in CD209+ mDCs was analyzed. A representative histogram is shown in (D), and the XBP-1s+ ratio in CD209+ mDCs is shown in (E, F). (G) IL-6 and IL-23 concentrations in the culture supernatants were measured. mono, monomer; TAK, TAK-242; STF, STF-083010; XBP-1s, spliced X-box binding protein-1. Each dot indicates the value of one individual. Data represent the mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. P-values were determined by the Friedman test (B), the Mann–Whitney U-test (C), or Wilcoxon’s matched-pairs signed-rank test (E–G)
    Tlr4 Inhibitor, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tlr2+tlr4+inhibitor/pm39934862-95-4-18?v=Selleck+Chemicals
    Average 93 stars, based on 1 article reviews
    tlr4 inhibitor - by Bioz Stars, 2026-07
    93/100 stars
    		  Buy from Supplier
    concentration 10× tirap  (Novus Biologicals)
    91
    Novus Biologicals concentration 10× tirap
    Fig. 4 XBP-1s expression in α-synuclein-stimulated DCs. (A, B) mDCs generated from healthy subjects (Table 1) were cultured in the presence or absence of high-dose (50 µg/ml) αS monomers or fibrils for 24 h. XBP-1s expression in CD209+ mDCs was analyzed. Gating strategies are shown in Supplementary Fig. 7. A representative histogram is shown in (A) and the XBP-1 s+ ratio in CD209+ mDCs (n = 7) is shown in (B). (C) Cryopreserved PBMCs from PD patients (n = 8) and age-matched controls (n = 5) were subjected to flow cytometric analysis (Supplementary Table 4). Gating strategies are shown in Supplementary Fig. 12. The XBP-1 s+ ratio in CD1c+ type 2 conventional DCs (cDC2s) is shown. (D–G) mDCs generated from healthy subjects (Table 1, n = 6) were treated with a <t>TLR4</t> inhibitor, TAK-242 (60 µM) (D, E), or an IRE1-XBP-1s inhibitor, STF-083010 (120 µM) (F, G), for 2 h prior to 24 h stimulation with high-dose (50 µg/ml) αS fibrils. Vehicle containing the same concentration of DMSO was used as a control. (D–F) XBP-1s expression in CD209+ mDCs was analyzed. A representative histogram is shown in (D), and the XBP-1s+ ratio in CD209+ mDCs is shown in (E, F). (G) IL-6 and IL-23 concentrations in the culture supernatants were measured. mono, monomer; TAK, TAK-242; STF, STF-083010; XBP-1s, spliced X-box binding protein-1. Each dot indicates the value of one individual. Data represent the mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. P-values were determined by the Friedman test (B), the Mann–Whitney U-test (C), or Wilcoxon’s matched-pairs signed-rank test (E–G)
    Concentration 10× Tirap, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tlr2+tlr4+inhibitor/pmc08509240-57-19-29?v=Novus+Biologicals
    Average 91 stars, based on 1 article reviews
    concentration 10× tirap - by Bioz Stars, 2026-07
    91/100 stars
    		  Buy from Supplier
    tlr2 4 inhibitor peptide  (Novus Biologicals)
    91
    Novus Biologicals tlr2 4 inhibitor peptide
    Fig. 4 XBP-1s expression in α-synuclein-stimulated DCs. (A, B) mDCs generated from healthy subjects (Table 1) were cultured in the presence or absence of high-dose (50 µg/ml) αS monomers or fibrils for 24 h. XBP-1s expression in CD209+ mDCs was analyzed. Gating strategies are shown in Supplementary Fig. 7. A representative histogram is shown in (A) and the XBP-1 s+ ratio in CD209+ mDCs (n = 7) is shown in (B). (C) Cryopreserved PBMCs from PD patients (n = 8) and age-matched controls (n = 5) were subjected to flow cytometric analysis (Supplementary Table 4). Gating strategies are shown in Supplementary Fig. 12. The XBP-1 s+ ratio in CD1c+ type 2 conventional DCs (cDC2s) is shown. (D–G) mDCs generated from healthy subjects (Table 1, n = 6) were treated with a <t>TLR4</t> inhibitor, TAK-242 (60 µM) (D, E), or an IRE1-XBP-1s inhibitor, STF-083010 (120 µM) (F, G), for 2 h prior to 24 h stimulation with high-dose (50 µg/ml) αS fibrils. Vehicle containing the same concentration of DMSO was used as a control. (D–F) XBP-1s expression in CD209+ mDCs was analyzed. A representative histogram is shown in (D), and the XBP-1s+ ratio in CD209+ mDCs is shown in (E, F). (G) IL-6 and IL-23 concentrations in the culture supernatants were measured. mono, monomer; TAK, TAK-242; STF, STF-083010; XBP-1s, spliced X-box binding protein-1. Each dot indicates the value of one individual. Data represent the mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. P-values were determined by the Friedman test (B), the Mann–Whitney U-test (C), or Wilcoxon’s matched-pairs signed-rank test (E–G)
    Tlr2 4 Inhibitor Peptide, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tlr2+tlr4+inhibitor/pm33559894-25-29-35?v=Novus+Biologicals
    Average 91 stars, based on 1 article reviews
    tlr2 4 inhibitor peptide - by Bioz Stars, 2026-07
    91/100 stars
    		  Buy from Supplier
    tlr2 tlr4 inhibitor  (Novus Biologicals)
    91
    Novus Biologicals tlr2 tlr4 inhibitor
    Fig. 4 XBP-1s expression in α-synuclein-stimulated DCs. (A, B) mDCs generated from healthy subjects (Table 1) were cultured in the presence or absence of high-dose (50 µg/ml) αS monomers or fibrils for 24 h. XBP-1s expression in CD209+ mDCs was analyzed. Gating strategies are shown in Supplementary Fig. 7. A representative histogram is shown in (A) and the XBP-1 s+ ratio in CD209+ mDCs (n = 7) is shown in (B). (C) Cryopreserved PBMCs from PD patients (n = 8) and age-matched controls (n = 5) were subjected to flow cytometric analysis (Supplementary Table 4). Gating strategies are shown in Supplementary Fig. 12. The XBP-1 s+ ratio in CD1c+ type 2 conventional DCs (cDC2s) is shown. (D–G) mDCs generated from healthy subjects (Table 1, n = 6) were treated with a <t>TLR4</t> inhibitor, TAK-242 (60 µM) (D, E), or an IRE1-XBP-1s inhibitor, STF-083010 (120 µM) (F, G), for 2 h prior to 24 h stimulation with high-dose (50 µg/ml) αS fibrils. Vehicle containing the same concentration of DMSO was used as a control. (D–F) XBP-1s expression in CD209+ mDCs was analyzed. A representative histogram is shown in (D), and the XBP-1s+ ratio in CD209+ mDCs is shown in (E, F). (G) IL-6 and IL-23 concentrations in the culture supernatants were measured. mono, monomer; TAK, TAK-242; STF, STF-083010; XBP-1s, spliced X-box binding protein-1. Each dot indicates the value of one individual. Data represent the mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. P-values were determined by the Friedman test (B), the Mann–Whitney U-test (C), or Wilcoxon’s matched-pairs signed-rank test (E–G)
    Tlr2 Tlr4 Inhibitor, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tlr2+tlr4+inhibitor/pmc07604950-93-22-24?v=Novus+Biologicals
    Average 91 stars, based on 1 article reviews
    tlr2 tlr4 inhibitor - by Bioz Stars, 2026-07
    91/100 stars
    		  Buy from Supplier
    tlr2 tlr4 tir domain  (Novus Biologicals)
    90
    Novus Biologicals tlr2 tlr4 tir domain
    Fig. 4 XBP-1s expression in α-synuclein-stimulated DCs. (A, B) mDCs generated from healthy subjects (Table 1) were cultured in the presence or absence of high-dose (50 µg/ml) αS monomers or fibrils for 24 h. XBP-1s expression in CD209+ mDCs was analyzed. Gating strategies are shown in Supplementary Fig. 7. A representative histogram is shown in (A) and the XBP-1 s+ ratio in CD209+ mDCs (n = 7) is shown in (B). (C) Cryopreserved PBMCs from PD patients (n = 8) and age-matched controls (n = 5) were subjected to flow cytometric analysis (Supplementary Table 4). Gating strategies are shown in Supplementary Fig. 12. The XBP-1 s+ ratio in CD1c+ type 2 conventional DCs (cDC2s) is shown. (D–G) mDCs generated from healthy subjects (Table 1, n = 6) were treated with a <t>TLR4</t> inhibitor, TAK-242 (60 µM) (D, E), or an IRE1-XBP-1s inhibitor, STF-083010 (120 µM) (F, G), for 2 h prior to 24 h stimulation with high-dose (50 µg/ml) αS fibrils. Vehicle containing the same concentration of DMSO was used as a control. (D–F) XBP-1s expression in CD209+ mDCs was analyzed. A representative histogram is shown in (D), and the XBP-1s+ ratio in CD209+ mDCs is shown in (E, F). (G) IL-6 and IL-23 concentrations in the culture supernatants were measured. mono, monomer; TAK, TAK-242; STF, STF-083010; XBP-1s, spliced X-box binding protein-1. Each dot indicates the value of one individual. Data represent the mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. P-values were determined by the Friedman test (B), the Mann–Whitney U-test (C), or Wilcoxon’s matched-pairs signed-rank test (E–G)
    Tlr2 Tlr4 Tir Domain, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tlr2+tlr4+inhibitor/pm30635391-76-20-29?v=Novus+Biologicals
    Average 90 stars, based on 1 article reviews
    tlr2 tlr4 tir domain - by Bioz Stars, 2026-07
    90/100 stars
    		  Buy from Supplier
    tlr4 tirap inhibitor nbp2 26245  (Novus Biologicals)
    91
    Novus Biologicals tlr4 tirap inhibitor nbp2 26245
    Fig. 4 XBP-1s expression in α-synuclein-stimulated DCs. (A, B) mDCs generated from healthy subjects (Table 1) were cultured in the presence or absence of high-dose (50 µg/ml) αS monomers or fibrils for 24 h. XBP-1s expression in CD209+ mDCs was analyzed. Gating strategies are shown in Supplementary Fig. 7. A representative histogram is shown in (A) and the XBP-1 s+ ratio in CD209+ mDCs (n = 7) is shown in (B). (C) Cryopreserved PBMCs from PD patients (n = 8) and age-matched controls (n = 5) were subjected to flow cytometric analysis (Supplementary Table 4). Gating strategies are shown in Supplementary Fig. 12. The XBP-1 s+ ratio in CD1c+ type 2 conventional DCs (cDC2s) is shown. (D–G) mDCs generated from healthy subjects (Table 1, n = 6) were treated with a <t>TLR4</t> inhibitor, TAK-242 (60 µM) (D, E), or an IRE1-XBP-1s inhibitor, STF-083010 (120 µM) (F, G), for 2 h prior to 24 h stimulation with high-dose (50 µg/ml) αS fibrils. Vehicle containing the same concentration of DMSO was used as a control. (D–F) XBP-1s expression in CD209+ mDCs was analyzed. A representative histogram is shown in (D), and the XBP-1s+ ratio in CD209+ mDCs is shown in (E, F). (G) IL-6 and IL-23 concentrations in the culture supernatants were measured. mono, monomer; TAK, TAK-242; STF, STF-083010; XBP-1s, spliced X-box binding protein-1. Each dot indicates the value of one individual. Data represent the mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. P-values were determined by the Friedman test (B), the Mann–Whitney U-test (C), or Wilcoxon’s matched-pairs signed-rank test (E–G)
    Tlr4 Tirap Inhibitor Nbp2 26245, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 91/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/tlr2+tlr4+inhibitor/pm28132881-95-6-15?v=Novus+Biologicals
    Average 91 stars, based on 1 article reviews
    tlr4 tirap inhibitor nbp2 26245 - by Bioz Stars, 2026-07
    91/100 stars
    		  Buy from Supplier

    Image Search Results


    Fig. 4 XBP-1s expression in α-synuclein-stimulated DCs. (A, B) mDCs generated from healthy subjects (Table 1) were cultured in the presence or absence of high-dose (50 µg/ml) αS monomers or fibrils for 24 h. XBP-1s expression in CD209+ mDCs was analyzed. Gating strategies are shown in Supplementary Fig. 7. A representative histogram is shown in (A) and the XBP-1 s+ ratio in CD209+ mDCs (n = 7) is shown in (B). (C) Cryopreserved PBMCs from PD patients (n = 8) and age-matched controls (n = 5) were subjected to flow cytometric analysis (Supplementary Table 4). Gating strategies are shown in Supplementary Fig. 12. The XBP-1 s+ ratio in CD1c+ type 2 conventional DCs (cDC2s) is shown. (D–G) mDCs generated from healthy subjects (Table 1, n = 6) were treated with a TLR4 inhibitor, TAK-242 (60 µM) (D, E), or an IRE1-XBP-1s inhibitor, STF-083010 (120 µM) (F, G), for 2 h prior to 24 h stimulation with high-dose (50 µg/ml) αS fibrils. Vehicle containing the same concentration of DMSO was used as a control. (D–F) XBP-1s expression in CD209+ mDCs was analyzed. A representative histogram is shown in (D), and the XBP-1s+ ratio in CD209+ mDCs is shown in (E, F). (G) IL-6 and IL-23 concentrations in the culture supernatants were measured. mono, monomer; TAK, TAK-242; STF, STF-083010; XBP-1s, spliced X-box binding protein-1. Each dot indicates the value of one individual. Data represent the mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. P-values were determined by the Friedman test (B), the Mann–Whitney U-test (C), or Wilcoxon’s matched-pairs signed-rank test (E–G)

    Journal: Journal of neuroinflammation

    Article Title: α-Synuclein orchestrates Th17 responses as antigen and adjuvant in Parkinson's disease.

    doi: 10.1186/s12974-025-03359-w

    Figure Lengend Snippet: Fig. 4 XBP-1s expression in α-synuclein-stimulated DCs. (A, B) mDCs generated from healthy subjects (Table 1) were cultured in the presence or absence of high-dose (50 µg/ml) αS monomers or fibrils for 24 h. XBP-1s expression in CD209+ mDCs was analyzed. Gating strategies are shown in Supplementary Fig. 7. A representative histogram is shown in (A) and the XBP-1 s+ ratio in CD209+ mDCs (n = 7) is shown in (B). (C) Cryopreserved PBMCs from PD patients (n = 8) and age-matched controls (n = 5) were subjected to flow cytometric analysis (Supplementary Table 4). Gating strategies are shown in Supplementary Fig. 12. The XBP-1 s+ ratio in CD1c+ type 2 conventional DCs (cDC2s) is shown. (D–G) mDCs generated from healthy subjects (Table 1, n = 6) were treated with a TLR4 inhibitor, TAK-242 (60 µM) (D, E), or an IRE1-XBP-1s inhibitor, STF-083010 (120 µM) (F, G), for 2 h prior to 24 h stimulation with high-dose (50 µg/ml) αS fibrils. Vehicle containing the same concentration of DMSO was used as a control. (D–F) XBP-1s expression in CD209+ mDCs was analyzed. A representative histogram is shown in (D), and the XBP-1s+ ratio in CD209+ mDCs is shown in (E, F). (G) IL-6 and IL-23 concentrations in the culture supernatants were measured. mono, monomer; TAK, TAK-242; STF, STF-083010; XBP-1s, spliced X-box binding protein-1. Each dot indicates the value of one individual. Data represent the mean ± SD. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001. P-values were determined by the Friedman test (B), the Mann–Whitney U-test (C), or Wilcoxon’s matched-pairs signed-rank test (E–G)

    Article Snippet: For inhibitor experiments, a TLR4 inhibitor (TAK-242), TLR1/2 inhibitor (TLR2-IN-C29), or XBP-1 s inhibitor (STF-083010) was purchased from Selleck Chem (Houston, TX, USA).

    Techniques: Expressing, Generated, Cell Culture, Concentration Assay, Control, Binding Assay, MANN-WHITNEY